title: Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.
abstract: OBJECTIVE
  The physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) is common in medical examinations of the digestive tract conducted using FDG-positron emission tomography (PET). The aim of this study was to determine the effects of a proton pump inhibitor (PPI) on the physiological FDG accumulation in the digestive tract.
  
  
  METHODS
  A total of 130 patients examined from July 2007 to October 2008 were included in the final analysis. A PPI was administered orally prior to FDG-PET in 65 patients. The remaining 65 patients underwent FDG-PET without administration of the PPI. The assessments used visual and quantitative evaluations.
  
  
  RESULTS
  Visual evaluation showed that physiological FDG accumulation in the stomach was significantly reduced (p = 0.037) in the PPI group compared with the control group. The quantitative evaluation also revealed a significant reduction in the maximum standardized uptake values (SUV(max)) in the stomach in the PPI group compared with the control group (p < 0.0001). Physiological FDG accumulation in the colon showed a decreasing trend on visual evaluation in the PPI group compared with the control group, and the quantitative evaluation found a significant reduction in the physiological FDG accumulation in the colon in the PPI group (p = 0.045).
  
  
  CONCLUSIONS
  The oral administration of a PPI was effective for reducing the physiological accumulation of the FDG in the alimentary tract. However, based on the error associated with SUV(max) measurement, a quantitative evaluation should therefore be combined with the visual evaluation.
authors: Department of Surgical Oncology (Surgery I), Dokkyo Medical University, 880 Kitakobayashi, Mibu-machi, Tochigi 321-0293, Japan. y-domeki@dokkyomed.ac.jp
authors: Yasushi
authors: Y
authors: Domeki
authors: Erena
authors: E
authors: Yamazaki
authors: Akira
authors: A
authors: Matsuura
authors: Kazuhiro
authors: K
authors: Kitajima
authors: Koji
authors: K
authors: Murakami
authors: Hiroyuki
authors: H
authors: Kato
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003106:Colon / Q000187:drug effects / Q000378:metabolism*; D004334:Drug Administration Schedule; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009369:Neoplasms / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D064750:Rabeprazole; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D013270:Stomach / Q000187:drug effects; D014018:Tissue Distribution / Q000187:drug effects; D014057:Tomography, X-Ray Computed
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D064750:Rabeprazole